FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a pharmaceutical composition for parenteral drop introduction, intended for treating non-infectious liver diseases. Proposed composition comprises a complex of active substances: 10–30 mg of sodium flavinadenine dinucleotide, 100 mg of nicotinamide adenine dinucleotide phosphate, 60 mg pyridoxalphosphate hydrate, 1 mg methylcobalamin, 600–3,000 mg glutathione, 12.5 mg of orotic acid, 12.5 mg of adenosine phosphate, 106 mg of monoammonium glycyrrhizinate (80 mg in terms of glycyrrhizinic acid), 750 mg of L-methionine, 200 mg of L-cysteine hydrochloride, 800 mg of L-glycine, 100–250 mg of dexpanthenol, 1–3 mg of biotin, 15 mg of folic acid, 25 mg of alpha-lipoic (thioctic) acid, 25 mg of Ubidecarenone, 1,000 mg of ascorbic acid and distilled water (up to 500 ml).
EFFECT: invention provides extending the range of products for treating pathological processes non-infectious genesis in liver.
1 cl, 3 ex
